Cabaletta Bio Inc
CABA2.190USD
+0.010+0.46%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
200.28MCap. mercado
PérdidaP/E TTM
Más Datos de Cabaletta Bio Inc Compañía
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Información de la empresa
Símbolo de cotizaciónCABA
Nombre de la empresaCabaletta Bio Inc
Fecha de salida a bolsaOct 25, 2019
Director ejecutivoDr. Steven Nichtberger, M.D.
Número de empleados161
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 25
Dirección2929 Arch Street
CiudadPHILADELPHIA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal19104
Teléfono12677593100
Sitio Webhttps://www.cabalettabio.com/
Símbolo de cotizaciónCABA
Fecha de salida a bolsaOct 25, 2019
Director ejecutivoDr. Steven Nichtberger, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
T. Rowe Price Investment Management, Inc.
7.43%
Jennison Associates LLC
6.58%
Cormorant Asset Management, LP
5.47%
Otro
60.29%
Accionistas
Accionistas
Proporción
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
T. Rowe Price Investment Management, Inc.
7.43%
Jennison Associates LLC
6.58%
Cormorant Asset Management, LP
5.47%
Otro
60.29%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
34.02%
Hedge Fund
31.57%
Investment Advisor/Hedge Fund
10.03%
Research Firm
4.01%
Individual Investor
1.65%
Venture Capital
0.11%
Bank and Trust
0.04%
Otro
18.56%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
333
45.33M
50.39%
-18.00M
2025Q1
343
38.78M
72.92%
-24.88M
2024Q4
342
40.39M
82.63%
-20.01M
2024Q3
330
50.24M
102.85%
-12.34M
2024Q2
325
53.21M
110.27%
-11.74M
2024Q1
310
53.11M
110.79%
-5.05M
2023Q4
269
50.62M
118.36%
-623.67K
2023Q3
244
42.61M
108.50%
-4.28M
2023Q2
218
38.30M
97.94%
+637.03K
2023Q1
208
26.57M
91.08%
-5.98M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bain Capital Life Sciences Investors, LLC
2.76M
3.07%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
3.63M
4.04%
--
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.97M
4.41%
-103.98K
-2.55%
Mar 31, 2025
Jennison Associates LLC
2.43M
2.71%
-78.33K
-3.12%
Mar 31, 2025
The Vanguard Group, Inc.
2.84M
3.16%
-23.48K
-0.82%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
